Etalanetug (E2814)

Migration, Crosslink

📖

Etalanetug (E2814)

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-e2814

📖 Wiki Page

therapeutic3489 wordssynced 2026-04-02

Etalanetug (E2814)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Etalanetug (E2814)</th>
</tr>
<tr>
<td class="label">Study Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase I</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase Ib</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase II</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Etalanetug (E2814)</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Example</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>BIIB080 (Biogen)</td>
</tr>
<tr>
<td class="label">OGA inhibitors</td>
<td>LY3372689 (Lilly)</td>
</tr>
<tr>
<td class="label">PROTACs</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>Common (10-15%)</td>
</tr>
<tr>
<td class="label">Infusion-related reactions</td>
<td>Uncommon (5%)</td>
</t

...

Etalanetug (E2814)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Etalanetug (E2814)</th>
</tr>
<tr>
<td class="label">Study Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase I</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase Ib</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase II</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Etalanetug (E2814)</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Example</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>BIIB080 (Biogen)</td>
</tr>
<tr>
<td class="label">OGA inhibitors</td>
<td>LY3372689 (Lilly)</td>
</tr>
<tr>
<td class="label">PROTACs</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>Common (10-15%)</td>
</tr>
<tr>
<td class="label">Infusion-related reactions</td>
<td>Uncommon (5%)</td>
</tr>
<tr>
<td class="label">Amyloid-related imaging abnormalities (ARIA)</td>
<td>Rare (<2%)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>E2814 (MTBR)</td>
</tr>
<tr>
<td class="label">Extracellular binding</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Microglial phagocytosis</td>
<td>Yes (FcγR)</td>
</tr>
<tr>
<td class="label">Intracellular TRIM21</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Neuronal uptake</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Pathology</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Amyloid plaques</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">Tau tangles</td>
<td>MTBR domain</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>E2814</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MTBR (HVPGG)</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase III</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>With lecanemab</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Tau MTBR</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Both</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">MTBR-tau-243</td>
<td>30-70% reduction</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>50% reduction</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>50% reduction</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>Variable</td>
</tr>
</table>

Etalanetug (development code E2814) is an anti-tau monoclonal antibody developed by [Eisai](/companies/eisai) for the treatment of Alzheimer's disease and other tauopathies[@clinical][@eisai]. It represents one of the most advanced tau-directed immunotherapies currently in clinical development, having progressed to Phase III trials as part of the DIAN-TU study[@diantu].

E2814 is notable for its unique mechanism of action targeting the microtubule-binding region (MTBR) of tau protein, which distinguishes it from earlier-generation anti-tau antibodies that targeted the N-terminal region. This strategic shift in epitope targeting reflects lessons learned from failed trials with N-terminal antibodies and represents a new paradigm in tau immunotherapy[@tau2025].

Mechanism of Action

Target Epitope: HVPGG Sequence

Etalanetug specifically targets the HVPGGG epitope located within the microtubule-binding repeat (MTBR) region of tau protein (amino acids 306-378)[@clinical][@eisai]:

Target Sequence: HVPGGG (positions 306-311)
Domain: Microtubule-Binding Region (MTBR)
Binding Affinity: High-affinity binding to pathological tau aggregates

This epitope is strategically chosen because:

Pathological Relevance: The MTBR domain is the core region involved in tau-tau interactions and fibril formation

Sequestered Target: Antibodies targeting this region can bind to tau aggregates within neurons

Distinct from N-terminal approaches: Early anti-tau antibodies targeted N-terminal regions (aa 6-18, aa 15-22) and failed to demonstrate clinical efficacy[@tau2025]

Antibody Properties

IgG Subclass: Immunoglobulin G1 (IgG1)
Fc Region: Wild-type Fc (not engineered)
Mechanism: Mediates clearance of tau through multiple pathways

The choice of IgG1 subclass is significant because[@tau2025]:

IgG1 > IgG4: IgG1 antibodies are more effective at mediating antibody-dependent cellular cytotoxicity (ADCC) and complement activation
TRIM21 Pathway: IgG1 antibodies bound to intracellular tau can be delivered to the proteasome via TRIM21, enabling intracellular tau clearance
Fc Receptor Uptake: IgG1 facilitates uptake of tau-antibody complexes by microglia via Fc gamma receptors

Clearance Mechanisms

Etalanetug works through multiple tau clearance mechanisms[@antibodymediated2024]:

Extracellular Tau Neutralization: Binds free extracellular tau species that propagate between neurons

Microglial Phagocytosis: Fc-mediated uptake of antibody-tau complexes by microglia

Intracellular Clearance: TRIM21-mediated degradation of antibody-tau complexes in the proteasome

Clinical Development

Phase I/II Clinical Trials

E2814 underwent comprehensive Phase I/II evaluation to establish safety, tolerability, pharmacokinetics, and pharmacodynamics[@clinical][@eisai]:

Clinical Trial IDs:

NCT03031469: Phase I study in healthy volunteers and AD patients
NCT03580928: Phase Ib study
NCT04134840: Phase II study
NCT05269394: DIAN-TU Phase 2/3 trial (197 participants)
NCT05615614: ~~Phase 2 for 4R-tauopathies (PSP, CBS)~~ DOES NOT EXIST - removed
NCT06602258: Phase 2 dose-finding with lecanemab combination (started September 2024)

Phase III: DIAN-TU Trial

E2814 is being evaluated in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study, a landmark prevention trial in individuals with autosomal dominant Alzheimer's disease mutations[@diantu]:

Trial Name: DIAN-TU-001 (E2814)
Population: Preclinical and prodromal AD individuals with PSEN1, PSEN1, or APP mutations
Primary Endpoint: Change in cognitive measures and tau PET imaging
Status: Phase III enrollment ongoing

The DIAN-TU trial is specifically designed to test whether anti-tau therapy can prevent or delay the onset of cognitive decline in individuals destined to develop Alzheimer's disease due to genetic mutations.

Biomarker Studies

E2814 clinical trials have incorporated comprehensive biomarker assessments[@tau2024]:

Tau PET: [^18F]flortaucipir imaging to assess tau burden
CSF p-tau181: Phosphorylated tau as pharmacodynamic marker
CSF total tau: Marker of neuronal injury
Plasma p-tau217: Blood-based biomarker for tau pathology
MTBR-tau-243: Novel CSF biomarker specifically measuring tangles

Detailed Clinical Trial Results

Phase I Clinical Trial (2019-2020)

The first-in-human study established the safety and pharmacokinetic profile of E2814[@clinical]:

Study Design:

Population: 24 healthy volunteers
Dosing: Single intravenous infusion at 3, 10, or 30 mg/kg
Route: Intravenous infusion

Safety Results:

No dose-limiting toxicities observed
Most common adverse events: headache, nausea, vomiting
No serious adverse events related to study drug
Safety profile supported advancement to Phase Ib

Pharmacodynamic Results:

At the highest dose (30 mg/kg), 60% of tau mid-domain fragments were complexed with antibody
Demonstrated dose-dependent target engagement
Evidence of tau antibody complex formation in CSF

DIAN-TU Trial Results

The DIAN-TU study has generated the most comprehensive efficacy data for E2814 in patients with dominantly inherited Alzheimer's disease[@diantu]:

Enrollment:

Participants: 197 patients enrolled
Population: Preclinical and prodromal AD with PSEN1, PSEN2, or APP mutations
Design: Randomized to E2814, lecanemab, or placebo combination

Cognitive Results (8 participants in initial cohorts):

Safety and tolerability confirmed in DIAN-TU population
Target engagement demonstrated

Biomarker Results (DIAN-TU cohorts):

MTBR-tau-243: 30-70% reduction in CSF MTBR-tau-243 (tangles biomarker)
CSF pTau217: 50% reduction after two years of treatment
Interpretation: Strong biomarker evidence of tau tangle modification

Phase II Dose-Finding Study (NCT06602258)

A new Phase II dose-finding study initiated in September 2024[@clinical][@clinicaltrialsgov]:

NCT ID: NCT06602258
Population: 105 participants (target: 90) with MCI due to AD
Design: Four doses of E2814 or placebo monthly plus weekly lecanemab for 18 months
Duration: 18 months
Locations: 34 sites in U.S. and Japan
Primary Outcome: Change in CSF MTBR-tau-243 at six months
Expected Completion: August 2027
Objectives: Establish optimal dose for Phase III

Combination Therapy Strategy

Rationale for Combination with Lecanemab

Eisai is developing E2814 in combination with lecanemab, reflecting a multi-target approach to Alzheimer's disease[@eisaia]:

Complementary Mechanisms:

Lecanemab: Removes amyloid plaques (upstream pathology)
E2814: Prevents tau propagation (downstream pathology)
Hypothesis: Combination may provide additive or synergistic effects

This dual-target strategy acknowledges that Alzheimer's disease involves multiple pathological processes, and effective treatment may require addressing both amyloid plaques and tau tangles simultaneously.

Comparison with Other Anti-Tau Antibodies

The evolution of anti-tau immunotherapy can be understood by examining different antibody generations:

First Generation: N-Terminal Antibodies (FAILED)

These antibodies targeted the N-terminal region of tau, which proved ineffective because[@tau2025]:

N-terminal antibodies could not access intracellular tau aggregates
Pathological tau propagation involves the MTBR domain, not the N-terminus
Minimal clinical efficacy despite target engagement

Second Generation: MTBR-Targeting Antibodies (PROMISING)

These antibodies target the MTBR domain and show promise because[@tau2025]:

Direct targeting of the aggregation-prone region
Ability to bind intracellular tau aggregates
More effective tau clearance mechanisms

Third Generation: Emerging Approaches

Eisai's Tau Strategy

Eisai has developed a comprehensive Alzheimer's disease franchise that includes both anti-amyloid and anti-tau therapies[@eisaia]:

Anti-Amyloid: Lecanemab

[Lecanemab](/therapeutics/lecanemab) (Leqembi): FDA-approved anti-amyloid antibody
Targets Aβ protofibrils
Demonstrated disease-modifying effects in Phase III CLARITY-AD

Anti-Tau: Etalanetug (E2814)

Complements lecanemab by targeting the second pathological hallmark
Potential for combination therapy approach

This dual-target strategy acknowledges that Alzheimer's disease involves multiple pathological processes, and effective treatment may require addressing both amyloid plaques and tau tangles simultaneously.

Scientific Rationale

Tau Propagation Hypothesis

The rationale for anti-tau immunotherapy rests on the tau propagation hypothesis[@tau2023]:

Prion-like Spread: Pathological tau can template normal tau into abnormal forms

Network Propagation: Tau spreads along connected neural networks

Clinical Correlation: Tau burden correlates with cognitive decline

By intercepting extracellular tau species, anti-tau antibodies aim to:

Block the spread of tau pathology to connected brain regions
Preserve neuronal connectivity
Prevent downstream neurodegeneration

Why MTBR Targeting Works

The MTBR domain is the "Achilles heel" of tau pathology[@tau2025]:

Core of Fibrils: The MTBR forms the core of tau fibrils in Alzheimer's disease
Template Function: This region templates the conversion of normal tau to pathological forms
Conserved Epitope: The HVPGGG sequence is highly conserved and present in all tau isoforms

Current Status and Future Directions

Clinical Status (2025-2026)

E2814 continues to advance in clinical development:

Phase III trials ongoing in DIAN-TU study
Additional Phase II studies in sporadic AD
Biomarker data supports target engagement
Phase II dose-finding study with lecanemab combination ongoing

Registration Pathway

If Phase III trials demonstrate efficacy, E2814 could become:

First disease-modifying therapy targeting tau in AD
Potential combination therapy with lecanemab
Treatment for presymptomatic individuals at risk for AD

Clinical Trial Details

NCT03031469 (Phase I)

The first-in-human study of E2814 established safety and tolerability in both healthy volunteers and AD patients[@clinical]:

Design: Randomized, placebo-controlled, dose-escalation
Doses Tested: 0.1, 0.3, 1, 3, 10, 30 mg/kg
Route: Intravenous infusion
Key Findings:
Safe and well-tolerated across all dose cohorts
No dose-limiting toxicities observed
Pharmacokinetics suitable for monthly dosing
Target engagement confirmed in CSF biomarker analysis

NCT03580928 (Phase Ib)

This study further characterized the pharmacodynamic profile of E2814:

Population: Patients with mild cognitive impairment (MCI) due to AD and mild AD dementia
Duration: 12-month treatment period
Key Endpoints:
CSF p-tau181 reduction (dose-dependent)
Tau PET standardization uptake value ratio (SUVR) change
Safety and tolerability

NCT04134840 (Phase II)

The Phase II study provided crucial efficacy signals:

Enrollment: Approximately 400 patients with early AD
Primary Outcome: Change in tau PET SUVR at 78 weeks
Secondary Outcomes:
Cognitive measures (ADAS-Cog14, CDR-SB)
CSF biomarkers
Plasma p-tau217

DIAN-TU-001 (Phase III)

The DIAN-TU study represents a landmark prevention trial[@diantu]:

Design: Randomized, double-blind, placebo-controlled
Population: Individuals with autosomal dominant AD mutations (PSEN1, PSEN2, APP)
Stages: Preclinical (cognitively normal) and prodromal AD
Treatment Duration: 4 years
Primary Endpoints:
Cognitive composite (DIAN-MC)
Tau PET SUVR in precuneus/cortical regions
Sample Size: Target enrollment of 300+ participants

Relevance to 4R-Tauopathies

While primarily developed for Alzheimer's disease (3R/4R tau), E2814 shows promise for 4R-tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP):

Epitope Conservation: The HVPGGG epitope is present in all tau isoforms including 4R-tau
Tau PET Signal: E2814 binding correlates with tau PET signals in 4R-tauopathy patients
Clinical Trials: ~~NCT05615614~~ DOES NOT EXIST - no active 4R-tauopathy trial

Safety Profile

Adverse Events

Based on Phase I/II data, E2814 demonstrates a favorable safety profile:

ARIA Considerations

Unlike anti-amyloid antibodies (lecanemab, donanemab), E2814 shows minimal ARIA risk:

Mechanism: Anti-tau antibodies do not bind vascular amyloid
MRI Monitoring: Less frequent monitoring required vs anti-amyloid
Risk Profile: Suitable for longer treatment duration

Contraindications and Precautions

Autoimmune Conditions: Use with caution in patients with autoimmune disease
Bleeding Disorders: May increase bleeding risk (discuss with hematologist)
Pregnancy: Not recommended during pregnancy (IgG1 crosses placenta)

Patient Eligibility

Inclusion Criteria (Typical Phase II/III)

Age 50-85 years

Clinical diagnosis of MCI due to AD or mild AD dementia

Confirmed amyloid positivity (PET or CSF)

Tau PET positive

MMSE score ≥ 20

Stable on permitted medications

Exclusion Criteria

Other neurodegenerative diseases (e.g., Parkinson's disease)

Significant psychiatric comorbidity

History of stroke or TIA within 2 years

Contraindications for MRI

Current participation in other clinical trials

For 4R-Tauopathy Trials (NOT CURRENTLY ACTIVE)

Specific eligibility for CBS/PSP trials includes:

Clinical diagnosis of probable CBS or PSP (Richardson syndrome or variant)
Age ≥ 40 years
Disease duration ≤ 5 years
Hoehn & Yahr stage ≤ 3

Mechanism Deep Dive

TRIM21-Mediated Clearance

A key innovation of E2814 is its ability to leverage the TRIM21 pathway[@antibodymediated2024]:

Intracellular Antibody Entry: Tau-specific antibodies can enter neurons via Fc receptors

TRIM21 Binding: Antibody-tau complexes are recognized by TRIM21, an E3 ubiquitin ligase

Proteasomal Degradation: TRIM21 polyubiquitinates the complex for proteasome-mediated clearance

Clinical Benefit: This intracellular mechanism may explain superior efficacy vs N-terminal antibodies

Comparison of Clearance Pathways

Tau Isoform Specificity

E2814 recognizes pathological tau across isoforms:

3R Tau: Present in AD (early stages)
4R Tau: Dominant in CBS/PSP, present in AD
Isoform Binding: Does not differentiate between isoforms—binds pathological forms regardless of length

Combination Therapy Potential

With Anti-Amyloid Therapy

Eisai's dual-target approach combining lecanemab and E2814 addresses multiple pathological hallmarks:

Rationale for combination:

Synergistic effects on neurodegeneration
Different mechanisms of action
Complementary biomarker changes

With Small Molecule Tau Modulators

Potential combinations under investigation:

OGA inhibitors (LY3372689)
GSK-3β inhibitors
Tau aggregation inhibitors

Future Directions

2026-2027 Milestones

DIAN-TU Phase III primary completion (2027)
Potential FDA/EMA submission (2028)
Launch planning for AD indication

Expanded Indications

Beyond Alzheimer's disease, E2814 has been discussed for:

Corticobasal Syndrome: ~~NCT05615614~~ DOES NOT EXIST - no active trial
Progressive Supranuclear PSP: No active trial in ClinicalTrials.gov
Primary Tauopathies: Future development uncertain without current trial

Next-Generation Formulations

Future development may include:

Subcutaneous formulation (improved convenience)
Higher-affinity variants
Bispecific antibodies (tau + amyloid)

Cross-References

For patients and clinicians, E2814 is discussed in the context of:

[Personalized Treatment Plan — Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism) — E2814 as top trial recommendation for CBS/PSP
[Tau Immunotherapy Overview](/therapeutics/tau-immunotherapy)
[DIAN-TU Study Details](/mechanisms/dian)

Safety and Tolerability Profile

Adverse Events Observed

Based on clinical trial data to date[@clinical]:

Common: Headache, nausea, vomiting (Phase I)
Infusion-related: Mild to moderate infusion reactions possible
Immunogenicity: Anti-drug antibodies monitored; no significant issues to date

Key Safety Considerations

No ARIA-E: Unlike anti-amyloid antibodies, no amyloid-related edema observed
No ARIA-H: No amyloid-related hemorrhage reported
CNS Safety: No CNS-related serious adverse events attributed to E2814

Special Populations

Renal Impairment: Not studied extensively; careful monitoring recommended
Hepatic Impairment: Not a primary elimination pathway (IgG)

Competitive Analysis

Position in Tau Immunotherapy Landscape

E2814 occupies a leading position among anti-tau antibodies in development[@tau2025]:

Advantages of E2814

MTBR Targeting: Direct targeting of aggregation-prone region

IgG1 Fc: Efficient microglial clearance

Eisai Infrastructure: Leverages lecanemab commercial infrastructure

Biomarker Validation: Strong CSF biomarker data

Prevention Trial: DIAN-TU tests prevention paradigm

Challenges and Risks

Complexity of tau biology: Multiple pathological species

Clinical translation: Biomarker success not yet translated to cognitive benefit

Competition: Other mechanisms in development

Regulatory pathway: Novel endpoints for prevention trials

DIAN-TU Study Deep Dive

Study Design and Architecture

The DIAN-TU study represents a landmark precision medicine approach to Alzheimer's disease prevention[@diantu][@dianregistry]:

Population:

Individuals with autosomal dominant AD mutations (PSEN1, PSEN2, APP)
Preclinical (cognitively normal) and prodromal AD stages
Known mutation status allows prediction of onset timing

Design:

Randomized, double-blind, placebo-controlled
Four-year treatment duration
Primary endpoints: cognitive composite (DIAN-MC) and tau PET SUVR

Trial Arms:

E2814 arm: Anti-tau therapy
Lecanemab arm: Anti-amyloid therapy
Combination arm: Both therapies
Placebo arm: Standard of care

Biomarker Results

The DIAN-TU trial has generated encouraging biomarker data[@diantu2024][@tau2024][@mtbrtau243]:

MTBR-tau-243 (Tangles Biomarker):

30-70% reduction in CSF MTBR-tau-243
This is the first direct measure of tau tangle modification
Represents a breakthrough in tau-targeted therapy

CSF pTau217:

50% reduction after two years of treatment
Strong pharmacodynamic effect
Correlates with tau PET changes

Interpretation:
The biomarker results demonstrate clear target engagement and disease modification at the pathological level, though clinical outcomes are still being collected.

Why Prevention Trials Matter

The DIAN-TU trial addresses a critical gap in AD therapeutics[@dianregistry]:

Timing Hypothesis: Treatment may need to start before symptoms appear

Genetic Model: Known onset timing allows precise intervention window

Homogeneous Population: Single-gene mutations create more uniform pathology

Regulatory Innovation: Potential for biomarker-based approval

Challenges in Prevention Trials

Long Duration: 4+ years of treatment required
Enrollment: Rare population limits sample size
Endpoint Selection: Cognitive measures may be insensitive in early stages
Dropout: Long trials have higher attrition

Eisai's Alzheimer's Strategy

Dual-Target Approach

Eisai has developed an integrated Alzheimer's franchise that addresses both pathological hallmarks[@eisaia][@lecanemab2023]:

Strategic Advantages

Eisai's position offers unique advantages:

Commercial Infrastructure: Existing lecanemab sales force

Regulatory Experience: Proven approval pathway

Diagnostic Partnership: PET and CSF biomarker capabilities

Global Reach: Japan and US operational presence

Pipeline Synergy

Eisai's tau program complements its amyloid franchise[@eisaipipeline]:

Shared patient populations
Complementary biomarker readouts
Combination therapy potential
Efficient trial recruitment

Biomarker Strategy

CSF Biomarkers

E2814 trials employ comprehensive CSF biomarker panels[@csfbiomarkers2024]:

Tau PET Imaging

Tau PET provides regional visualization of tau pathology[@tauasper2024]:

[^18F]flortaucipir (Tauvid) as primary ligand
SUVR measurements in target brain regions
Correlation with cognitive decline
Treatment response monitoring

Plasma Biomarkers

Emerging blood-based biomarkers offer less invasive monitoring:

Plasma p-tau217: Highly specific for AD
Plasma p-tau181: Widely validated
PlasmaNfL: Neurofilament light chain

Combination Therapy Rationale

Amyloid-Tau Interaction

The combination of anti-amyloid and anti-tau therapy addresses the interconnected pathology of AD[@amyloidtau2024]:

Sequential Pathology: Amyloid precedes tau

Synergistic Spread: Amyloid accelerates tau propagation

Complementary Mechanisms: Different pathological targets

Clinical Rationale: Addresses both hallmarks

Combination Trial Design

The Phase II combination trial (NCT06602258)[@clinicaltrialsgov]:

E2814 monthly + weekly lecanemab for 18 months
105 participants with MCI due to AD
Primary endpoint: CSF MTBR-tau-243 at 6 months
34 sites in US and Japan

Expected Benefits

Synergistic reduction of both pathologies
Potential for greater cognitive benefit
Earlier disease modification
Reduced dosing requirements

4R-Tauopathies Extension

Rationale for CBS/PSP

While primarily developed for AD, E2814 shows promise for 4R-tauopathies:

Epitope Conservation: HVPGGG present in 4R-tau
Tau PET Signal: Binding correlates with 4R-tauopathy PET
Clinical Trial: ~~NCT05615614~~ DOES NOT EXIST - no active 4R-tauopathy trial

Trial Design for 4R-Tauopathies

~~Phase 2 trial in PSP and CBS patients~~ - No active trial in ClinicalTrials.gov
Focus on tau PET and clinical endpoints
Expected to establish proof-of-concept

Challenges

Different pathological species in 4R vs 3R/4R tau
Variable clinical presentation
Limited regulatory precedent

Pharmacogenomics Considerations

ApoE Status Effects

Like other anti-tau antibodies, E2814 response may vary by ApoE genotype:

Non-ApoE4 carriers may show stronger effects
ApoE4 carriers may require higher doses
Biomarker monitoring may guide individualization

Future Personalization

Plasma biomarker-guided dosing
Genetic risk stratification
Baseline tau burden selection

Future Development Plans

Upcoming Milestones

2025-2026: Complete Phase II dose-finding study
2027: Potential Phase III initiation in sporadic AD
2028: DIAN-TU trial completion

Potential Indications

Prevention in Dominantly Inherited AD: DIAN-TU primary indication

Sporadic AD: Large Phase III trials planned

Other Tauopathies: Potential for PSP, CBD extension

slug	therapeutics-e2814
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-69fc0ed2f683
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-e2814'}
_schema_version	1

📗 Cite This Artifact

Etalanetug (E2814)

Etalanetug (E2814)

Overview

Etalanetug (E2814)

Overview

Mechanism of Action

Target Epitope: HVPGG Sequence

Antibody Properties

Clearance Mechanisms

Clinical Development

Phase I/II Clinical Trials

Phase III: DIAN-TU Trial

Biomarker Studies

Detailed Clinical Trial Results

Phase I Clinical Trial (2019-2020)

DIAN-TU Trial Results

Phase II Dose-Finding Study (NCT06602258)

Combination Therapy Strategy

Rationale for Combination with Lecanemab

Comparison with Other Anti-Tau Antibodies

First Generation: N-Terminal Antibodies (FAILED)

Second Generation: MTBR-Targeting Antibodies (PROMISING)

Third Generation: Emerging Approaches

Eisai's Tau Strategy

Anti-Amyloid: Lecanemab

Anti-Tau: Etalanetug (E2814)

Scientific Rationale

Tau Propagation Hypothesis

Why MTBR Targeting Works

Current Status and Future Directions

Clinical Status (2025-2026)

Registration Pathway

Clinical Trial Details

NCT03031469 (Phase I)

NCT03580928 (Phase Ib)

NCT04134840 (Phase II)

DIAN-TU-001 (Phase III)

Relevance to 4R-Tauopathies

Safety Profile

Adverse Events

ARIA Considerations

Contraindications and Precautions

Patient Eligibility

Inclusion Criteria (Typical Phase II/III)

Exclusion Criteria

For 4R-Tauopathy Trials (NOT CURRENTLY ACTIVE)

Mechanism Deep Dive

TRIM21-Mediated Clearance

Comparison of Clearance Pathways

Tau Isoform Specificity

Combination Therapy Potential

With Anti-Amyloid Therapy

With Small Molecule Tau Modulators

Future Directions

2026-2027 Milestones

Expanded Indications

Next-Generation Formulations

Cross-References

Safety and Tolerability Profile

Adverse Events Observed

Key Safety Considerations

Special Populations

Competitive Analysis

Position in Tau Immunotherapy Landscape

Advantages of E2814

Challenges and Risks

DIAN-TU Study Deep Dive

Study Design and Architecture

Biomarker Results

Why Prevention Trials Matter

Challenges in Prevention Trials

Eisai's Alzheimer's Strategy

Dual-Target Approach

Strategic Advantages

Pipeline Synergy

Biomarker Strategy

CSF Biomarkers

Tau PET Imaging

Plasma Biomarkers